Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SWITCH: Upadacitinib versus Adalimumab in moderate to severe rheumatoid arthritis with inadequate response to a single TNF inhibitor on methotrexate
2022-502578-18-00Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 4, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: DAS28-CRP ≤ 3.2 at Week 12. Started Oct 2023; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-502578-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502578-18-00.